팜젠사이언스

004720KOSPI의약품 제조업

57.0 / 100

Reference Date: 2026-07-24

Financial Score14.5 / 40

News Sentiment18.5 / 25

Momentum14.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Surged 23.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Palmgen Science operates in pharmaceuticals, healthcare, and real estate leasing, achieving 16.54 billion KRW in pharmaceutical sales and 650 million KRW in healthcare sales in 2025. Key products include Esomax (for digestive disorders), Bardifin (hypertension treatment), and Kvasitin (hyperlipidemia treatment), with the company enhancing competitiveness through new drug development and quality improvements.

Number of Employees

229people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

0.54Industry Average 0.815.5Point

Lower than industry avg (good)

ROE

-58.95Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

10.55Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼13.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.4% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 1Negative 0Average Sentiment Score 74

Neutral
[바이오스냅] 동화약품, 노사 화합 선언문 발표
동화약품의 노사 화합 선언이 팜젠사이언스와 직접적인 연관성이 없어 영향이 미미함.
Positive
팜젠사이언스, 국내 최초 8시간 지속 복합 비타민B '비타잉B' 출시
팜젠사이언스의 신규 비타민B 복합제 '비타잉B' 출시로 인해 시장 경쟁력 강화 및 매출 증대 기대.
Positive
[어바웃 C] 팜젠 전략위원장의 알에프바이오行, 에스테틱 사업 전면배....
팜젠사이언스의 전략적 이동으로 에스테틱 사업 확장이 예상되어 긍정적인 시장 반응이 기대됩니다.

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 3,475Won52-week high 4,92552-week low 2,710

1-month return6.0Point

1m +23.23% (strong rise)

Volume trend5.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0